JP2017535592A5 - - Google Patents

Download PDF

Info

Publication number
JP2017535592A5
JP2017535592A5 JP2017528854A JP2017528854A JP2017535592A5 JP 2017535592 A5 JP2017535592 A5 JP 2017535592A5 JP 2017528854 A JP2017528854 A JP 2017528854A JP 2017528854 A JP2017528854 A JP 2017528854A JP 2017535592 A5 JP2017535592 A5 JP 2017535592A5
Authority
JP
Japan
Prior art keywords
composition
active agent
use according
coating
weight percent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017528854A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535592A (ja
JP6686023B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/002345 external-priority patent/WO2016083891A1/en
Publication of JP2017535592A publication Critical patent/JP2017535592A/ja
Publication of JP2017535592A5 publication Critical patent/JP2017535592A5/ja
Application granted granted Critical
Publication of JP6686023B2 publication Critical patent/JP6686023B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017528854A 2014-11-25 2015-11-25 生物活性剤または生物活性剤類を送達する組成物および方法 Expired - Fee Related JP6686023B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462084387P 2014-11-25 2014-11-25
US62/084,387 2014-11-25
PCT/IB2015/002345 WO2016083891A1 (en) 2014-11-25 2015-11-25 Compositions and methods for delivering a bio-active agent or bio-active agents

Publications (3)

Publication Number Publication Date
JP2017535592A JP2017535592A (ja) 2017-11-30
JP2017535592A5 true JP2017535592A5 (enExample) 2019-01-10
JP6686023B2 JP6686023B2 (ja) 2020-04-22

Family

ID=56073684

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017528854A Expired - Fee Related JP6686023B2 (ja) 2014-11-25 2015-11-25 生物活性剤または生物活性剤類を送達する組成物および方法

Country Status (7)

Country Link
US (3) US10471070B2 (enExample)
EP (1) EP3223793B1 (enExample)
JP (1) JP6686023B2 (enExample)
KR (1) KR102511830B1 (enExample)
CN (1) CN107645951B (enExample)
CA (1) CA2968926C (enExample)
WO (1) WO2016083891A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3630042A4 (en) * 2017-05-30 2021-06-23 Eximore Ltd. COMPOSITIONS AND METHODS OF TREATMENT OF DRY EYE BY RELEASE OF ANTIBIOTIC MACROLIDE
CN111110636B (zh) * 2018-11-01 2022-09-27 复旦大学附属眼耳鼻喉科医院 使用纳米介孔氧化硅高效负载及缓释抗青光眼药物
US11207267B2 (en) 2019-10-02 2021-12-28 Segal Innovations LLC Bio-adhesive dissolving compounds and device
US12447045B2 (en) 2019-10-02 2025-10-21 Segal Innovations LLC Bio-adhesive dissolving compounds and device
WO2021113637A1 (en) * 2019-12-04 2021-06-10 Restore Vision, Llc. Ophthalmic formulations for the treatment of presbyopia
WO2022096931A2 (en) * 2020-11-09 2022-05-12 Eximore Ltd. Punctal plugs containing micelle-encapsulated ophthalmic pharmaceuticals and methods for making thereof
EP4346720A4 (en) 2021-05-28 2025-01-01 Sight Sciences, Inc. INTRAOCULAR DEVICES, SYSTEMS AND METHODS

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
EP1348437A3 (en) 1988-09-06 2003-11-19 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
EP2004172B1 (en) * 2006-03-31 2019-03-13 Mati Therapeutics Inc. Drug delivery structures and compositions for nasolacrimal system
CN101505695A (zh) * 2006-06-21 2009-08-12 庄臣及庄臣视力保护公司 用于递送活性试剂的泪点塞
UY30883A1 (es) * 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
EP2207529B1 (en) * 2007-09-07 2014-12-31 Mati Therapeutics Inc. Drug cores for sustained release of therapeutic agents
WO2009137777A2 (en) * 2008-05-08 2009-11-12 Replenish Pumps, Llc Implantable drug-delivery devices, and apparatus and methods for filling the devices
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
CA2728623A1 (en) * 2008-06-24 2010-01-21 Qlt Plug Delivery, Inc. Combination treatment of glaucoma
US20100158980A1 (en) * 2008-12-18 2010-06-24 Casey Kopczynski Drug delivery devices for delivery of therapeutic agents
JP2013526572A (ja) * 2010-05-17 2013-06-24 アエリエ・ファーマシューティカルズ・インコーポレーテッド 眼治療薬の送達のための薬物送達装置
US20120238994A1 (en) * 2010-12-22 2012-09-20 Martin Nazzaro Two-piece injectable drug delivery device with heat-cured seal
EP3967297A1 (en) 2011-04-29 2022-03-16 Allergan, Inc. Sustained release latanoprost implant
ES2727203T3 (es) * 2011-08-29 2019-10-14 Mati Therapeutics Inc Administración por liberación sostenida de agentes activos para tratar glaucoma e hipertensión ocular
CN111700880A (zh) 2012-05-03 2020-09-25 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子
JP2016515583A (ja) * 2013-03-27 2016-05-30 フォーサイト ヴィジョンファイブ、インク．ＦｏｒＳｉｇｈｔ ＶＩＳＩＯＮ５， Ｉｎｃ． オキュラー・インサートおよびその使用方法

Similar Documents

Publication Publication Date Title
MX2015015589A (es) Composiciones y metodos para el suministro de agentes activos hidrófobos.
JP2017105763A5 (enExample)
JP2015525757A5 (enExample)
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
BR112015018095A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
BR112015020453A8 (pt) "formas de dosagem de liberação prolongada orais de tofacitinibe e uso de tofacitinibe
JP2011518842A5 (enExample)
JP2015536939A5 (enExample)
BR112015030140A2 (pt) forma de dosagem farmacêutica sólida para liberação de pelo menos um ingrediente farmacêutico ativo na cavidade oral
AR065235A1 (es) Tapones puntuales y metodos de administracion de agentes terapeuticos
PH12014502331B1 (en) Orally available pharmaceutical formulation suitable for improved management of movement disorders
WO2015070234A3 (en) Neuroprotective compounds and use thereof
MX2022005650A (es) Agente terapeutico y agente profilactico para trastornos gastrointestinales funcionales y xerostomia.
MX380361B (es) Suspensiones orales fisica y quimicamente estables de givinostat.
JP2015508411A5 (enExample)
EP2364733A3 (en) Selegiline-containing adhesive preparation
TWD209759S (zh) 耳機
JP2016523943A5 (enExample)
EA201890703A1 (ru) Коллоидные частицы, предназначенные для применения в медицине
BR112015021769A2 (pt) composições farmacêuticas compreendendo um agente ativo
AR075058A1 (es) Composicion farmaceutica oral para uso en enfermedades respiratorias y proceso de fabricacion
AR119421A1 (es) Formulaciones farmacéuticas
JP2016014215A5 (ja) 花粉付着防止マスクの製造方法
JP2018513862A5 (enExample)
JP2016516430A5 (enExample)